Sjögren's Syndrome

You have full text access to this OnlineOpen article

Preclinical validation of salivary biomarkers for primary Sjögren's syndrome

  1. Shen Hu1,*,
  2. Kai Gao1,
  3. Rodney Pollard2,
  4. Martha Arellano-Garcia1,
  5. Hui Zhou1,
  6. Lei Zhang1,
  7. David Elashoff1,
  8. Cees G. M. Kallenberg2,
  9. Arjan Vissink2,
  10. David T. Wong1,§

Article first published online: 8 JUL 2010

DOI: 10.1002/acr.20289

Issue

Arthritis Care & Research

Arthritis Care & Research

Volume 62, Issue 11, pages 1633–1638, November 2010

Additional Information

How to Cite

Hu, S., Gao, K., Pollard, R., Arellano-Garcia, M., Zhou, H., Zhang, L., Elashoff, D., Kallenberg, C. G. M., Vissink, A. and Wong, D. T. (2010), Preclinical validation of salivary biomarkers for primary Sjögren's syndrome. Arthritis Care Res, 62: 1633–1638. doi: 10.1002/acr.20289

Author Information

  1. 1

    University of California, Los Angeles

  2. 2

    University Medical Center Groningen, University of Groningen, Groningen, The Netherlands

  1. §

    Dr. Wong has stock ownership or options in RNAmeTRIX.

*10833 Le Conte Avenue, Los Angeles, CA 90095

Publication History

  1. Issue published online: 2 NOV 2010
  2. Article first published online: 8 JUL 2010
  3. Manuscript Accepted: 28 JUN 2010
  4. Manuscript Received: 21 DEC 2009

Funded by

  • USPHS. Grant Number: R01-DE017593

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article with Supporting Information (HTML) Get PDF (277K)

REFERENCES

  • 1
    Fox RI. Sjögren's syndrome. Lancet 2005; 366: 321–31.
  • 2
    Nikolov NP, Illei GG. Pathogenesis of Sjögren's syndrome. Curr Opin Rheumatol 2009; 5: 465–70.
  • 3
    Meijer J, Pijpe J, Bootsma H, Vissink A, Kallenberg C. The future of biologic agents in the treatment of Sjögren's syndrome. Clin Rev Allergy Immunol 2007; 32: 292–7.
  • 4
    Pijpe J, Meijer JM, Bootsma H, van der Wal JE, Spijkervet FK, Kallenberg CG, et al. Clinical and histologic evidence of salivary gland restoration supports the efficacy of rituximab treatment in Sjögren's syndrome. Arthritis Rheum 2009; 60: 3251–6.
    Direct Link:
  • 5
    Meijer JM, Pijpe J, Vissink A, Kallenberg CG, Bootsma H. Treatment of primary Sjögren's syndrome with rituximab: extended follow-up, safety and efficacy of retreatment [letter]. Ann Rheum Dis 2009; 68: 284–5.
  • 6
    Pijpe J, van Imhoff GW, Spijkervet FK, Roodenburg JL, Wolbink GJ, Mansour K, et al. Rituximab treatment in patients with primary Sjögren's syndrome: an open-label phase II study. Arthritis Rheum 2005; 52: 2740–50.
    Direct Link:
  • 7
    Dass S, Bowman SJ, Vital EM, Ikeda K, Pease CT, Hamburger J, et al. Reduction of fatigue in Sjögren's syndrome with rituximab: results of a randomised, double-blind, placebo-controlled pilot study. Ann Rheum Dis 2008; 67: 1541–4.
  • 8
    Devauchelle-Pensec V, Pennec Y, Morvan J, Pers JO, Daridon C, Jousse-Joulin S, et al. Improvement of Sjögren's syndrome after two infusions of rituximab (anti-CD20). Arthritis Rheum 2007; 57: 310–7.
    Direct Link:
  • 9
    Gottenberg JE, Guillevin L, Lambotte O, Combe B, Allanore Y, Cantagrel A, et al. Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases. Ann Rheum Dis 2005; 64: 913–20.
  • 10
    Meijer JM, Meiners PM, Vissink A, Spijkervet FK, Abdulahad W, Kamminga N, et al. Effectiveness of rituximab treatment in primary Sjögren's syndrome: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2010; 62: 960–8.
    Direct Link:
  • 11
    Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL, Carsons SE, et al. Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 2002; 61: 554–8.
  • 12
    Franceschini F, Cavazzana I. Anti-Ro/SSA and La/SSB antibodies. Autoimmunity 2005; 38: 55–63.
  • 13
    Pijpe J, Kalk WW, van der Wal JE, Vissink A, Kluin PM, Roodenburg JL, et al. Parotid gland biopsy compared with labial biopsy in the diagnosis of patients with primary Sjogren's syndrome. Rheumatology (Oxford) 2007; 46: 335–41.
  • 14
    Hu S, Wang J, Meijer J, Ieong S, Xie Y, Yu T, et al. Salivary proteomic and genomic biomarkers for primary Sjögren's syndrome. Arthritis Rheum 2007; 56: 3588–600.
    Direct Link:
  • 15
    Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271–7.
    Direct Link:
  • 16
    Pijpe J, Kalk WW, Bootsma H, Spijkervet FK, Kallenberg CG, Vissink A. Progression of salivary gland dysfunction in patients with Sjögren's syndrome. Ann Rheum Dis 2007; 66: 107–12.
  • 17
    Hu Z, Zimmermann BG, Zhou H, Wang J, Henson BS, Yu W, et al. Exon-level expression profiling: a comprehensive transcriptome analysis of oral fluids. Clin Chem 2008; 54: 824–32.
  • 18
    Etzioni R, Kooperberg C, Pepe M, Smith R, Gann PH. Combining biomarkers to detect disease with application to prostate cancer. Biostatistics 2003; 4: 523–38.
  • 19
    Swaak A, Visch L, Zonneveld A. Diagnostic significance of salivary levels of β2-microglobulin in Sjögren's syndrome. Clin Rheumatol 1988; 7: 28–34.
  • 20
    Maddali BS, Campana G, D'Agata A, Palermo C, Bianucci G. The diagnosis value of β2-microglobulin and immunoglobulins in primary Sjögren's syndrome. Clin Rheumatol 1995; 14: 151–6.
  • 21
    Hjelmervik TO, Petersen K, Jonassen I, Jonsson R, Bolstad AI. Gene expression profiling of minor salivary glands clearly distinguishes primary Sjögren's syndrome patients from healthy control subjects. Arthritis Rheum 2005; 52: 1534–44.
    Direct Link:
  • 22
    Wei F, Patel P, Liao W, Chaudhry K, Zhang L, Arellano-Garcia M, et al. Electrochemical sensor for multiplex biomarkers detection. Clin Cancer Res 2009; 15: 4446–52.
View Full Article with Supporting Information (HTML) Get PDF (277K)